Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High – Here’s Why

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $59.94 and last traded at $59.60, with a volume of 447286 shares trading hands. The stock had previously closed at $57.13.

Analyst Ratings Changes

Several equities analysts have weighed in on KNSA shares. Canaccord Genuity Group raised their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a report on Wednesday, April 29th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Monday, May 4th. Finally, Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $60.86.

Kiniksa Pharmaceuticals International Trading Up 0.3%

The stock has a market capitalization of $4.56 billion, a PE ratio of 65.55 and a beta of 0.12. The business’s 50-day moving average is $51.70 and its two-hundred day moving average is $46.76.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.11 EPS. On average, analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current year.

Insider Buying and Selling

In other news, Director Barry D. Quart sold 13,099 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the transaction, the director owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This trade represents a 51.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 1,703 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $79,513.07. Following the completion of the sale, the chief operating officer owned 12,029 shares of the company’s stock, valued at $561,634.01. This trade represents a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently modified their holdings of the company. Amundi acquired a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Kiniksa Pharmaceuticals International by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after acquiring an additional 1,002 shares during the last quarter. Millennium Management LLC raised its position in shares of Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the period. Creative Planning acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $358,000. Finally, Quantbot Technologies LP acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth about $43,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.